Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
HGF receptor Met makes a hybrid with insulin receptor and acts as a regulator for insulin sensitivity in the liver. The present study tried to establish new antibody drug therapy for NASH using Met-activating antibody. Treatment with Met-activating antibody on STAM mice (NASH model) did not show the significant decreased blood sugar or fatty liver, compared with control. However, treatment with Met-activating antibody on hepatectomized cirrhotic liver showed significant recovery of fibrosis, inflammation and regeneration and this effects continuedfor long period. Met-activating antibody can be used as an antibody drug for organ regeneration.
|